Literature DB >> 3587916

Uveal melanomas near the optic disc or fovea. Visual results after proton beam irradiation.

J M Seddon, E S Gragoudas, K M Egan, R J Glynn, J E Munzenrider, M Austin-Seymour, M Goitein, L Verhey, M Urie, A Koehler.   

Abstract

Proximity to the disc and fovea is a risk factor for visual loss after proton beam irradiation of uveal melanomas. Of 562 eyes treated over a 10-year period with pretreatment visual acuity of 20/200 or better, 363 (64.6%) contained tumors within 2 disc diameters (DD) of the disc or fovea. Rates of visual loss after treatment to worse than 20/200 and causes of visual decline were evaluated using Kaplan-Meier analysis. Cumulative rates of visual loss among subjects with tumors near the disc or fovea were 33 and 47% 1 and 2 years after treatment compared to 17 and 28%, respectively, for subjects with tumors located farther from both structures. The leading cause of visual loss in the first year among eyes with tumors near the disc or fovea was retinal detachment. Controlling for other predictors of visual loss to worse than 20/200, location near the disc or fovea was independently related to visual loss primarily due to retinal detachment, cataract, and radiation retinopathy. Despite the unfavorable location of these tumors, over half of patients with 20/200 or better pretreatment visual acuity had useful vision 2 years after treatment.

Entities:  

Mesh:

Year:  1987        PMID: 3587916     DOI: 10.1016/s0161-6420(87)33439-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy.

Authors:  Nicholas Koch; Wayne D Newhauser; Uwe Titt; Dan Gombos; Kevin Coombes; George Starkschall
Journal:  Phys Med Biol       Date:  2008-02-25       Impact factor: 3.609

3.  Endoresection of choroidal melanoma.

Authors:  B Damato; C Groenewald; J McGalliard; D Wong
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

4.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

5.  Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma.

Authors:  I D Fabian; A W Stacey; V Papastefanou; L Al Harby; A K Arora; M S Sagoo; V M L Cohen
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

6.  Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.

Authors:  P Summanen; I Immonen; T Kivelä; P Tommila; J Heikkonen; A Tarkkanen
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

7.  Treatment of juxtapapillary melanomas.

Authors:  P K Lommatzsch; R Lommatzsch
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

8.  Radiation-induced optic neuropathy following brachytherapy of uveal melanomas.

Authors:  U Kellner; N Bornfeld; M H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-05       Impact factor: 3.117

Review 9.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

10.  Internal resection of posterior uveal melanomas.

Authors:  P J Kertes; J C Johnson; G A Peyman
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.